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Abstract
Background: The Affordable Medicines Facility - malaria (AMFm), implemented at national scale in eight African
countries or territories, subsidized quality-assured artemisinin combination therapy (ACT) and included communica-
tion campaigns to support implementation and promote appropriate anti-malarial use. This paper reports private
for-profit provider awareness of key features of the AMFm programme, and changes in provider knowledge of
appropriate malaria treatment.
Methods: This study had a non-experimental design based on nationally representative surveys of outlets stocking
anti-malarials before (2009/10) and after (2011) the AMFm roll-out.
Results: Based on data from over 19,500 outlets, results show that in four of eight settings, where communication
campaigns were implemented for 5–9 months, 76%-94% awareness of the AMFm ‘green leaf’ logo, 57%-74%
awareness of the ACT subsidy programme, and 52%-80% awareness of the correct recommended retail price (RRP)
of subsidized ACT were recorded. However, in the remaining four settings where communication campaigns were
implemented for three months or less, levels were substantially lower. In six of eight settings, increases of at least
10 percentage points in private for-profit providers’ knowledge of the correct first-line treatment for uncomplicated
malaria were seen; and in three of these the levels of knowledge achieved at endline were over 80%.
Conclusions: The results support the interpretation that, in addition to the availability of subsidized ACT, the
intensity of communication campaigns may have contributed to the reported levels of AMFm-related awareness
and knowledge among private for-profit providers. Future subsidy programmes for anti-malarials or other treatments
should similarly include communication activities.
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Background
Artemisinin-based combination therapy (ACT) is the
recommended first-line treatment for uncomplicated
Plasmodium falciparum infection throughout Africa,
however, its use remains far below need and differs be-
tween urban and rural areas [1]. The reasons for this
include unreliable public sector supply, high prices and
limited availability in the private sector, and patient self-
treatment with less expensive monotherapies [2]. In 2010,
an innovative ACT subsidy programme, the Affordable
Medicines Facility - malaria (AMFm), was launched at na-
tional scale in Ghana, Kenya, Madagascar, Niger, Nigeria,
Uganda, and Tanzania (mainland and Zanzibar) [3]. The
programme aimed to improve the availability of quality-
assured ACT, and was hosted by the Global Fund to Fight
AIDS, Tuberculosis and Malaria (Global Fund).
The AMFm intervention included three elements: (i)
price reductions through negotiations with ACT manufac-
turers; (ii) a buyer subsidy, via a co-payment by the Global
Fund to participating manufacturers, for purchases made
by eligible public, private, and non-governmental organisa-
tion importers; and (iii) interventions to support AMFm
implementation and promote appropriate anti-malarial use
[4]. All medicines subsidized through AMFm had a ‘green
leaf ’ logo on their packaging (see logo in Figure 1). Inter-
ventions to support AMFm implementation and promote
appropriate anti-malarial use included communication
campaigns, training of anti-malarial providers, setting of a
recommended retail price (RRP), pharmacovigilance and
post-marketing surveillance, and regulatory interventions
such as enforcement of the ban on oral artemisinin mono-
therapy sales and changes to the prescription-only status
of ACT.
Communication campaigns, including the use of mass
media, have been used alone or as components of inter-
ventions to address a variety of public health problems
in low and middle income countries including HIV pre-
vention, family planning promotion, and the use of
insecticide-treated bed nets for malaria control [5]. The
effectiveness of such campaigns on behaviour change
Figure 1 (clockwise from top left) AMFm ‘green leaf’ logo; examples of AMFm communication campaign materials from Niger,
Madagascar, Ghana and Kenya; and an example of commercial promotion for co-paid ACT from Ghana.
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has been the subject of a number of reviews, and re-
mains a key question for national and international pol-
icy makers [6-9]. In the context of AMFm, this is of
particular interest given the scale of resources devoted
to this component of the intervention ($42.3 million dis-
bursed for supporting interventions overall by the end of
2011) and the relative novelty of the approaches used,
such as the AMFm logo and RRPs.
This paper describes the implementation of the AMFm
communication and training interventions as part of the
overall AMFm intervention package. Private providers of
anti-malarials can be considered a key target group for
AMFm communication and training, given the geograph-
ical penetration of the private for-profit sector, as well as
the role of providers in product ordering, retail pricing,
point of sale promotion, and patient advice [10-18]. For this
reason, this paper focuses on the private for-profit sector,
and reports private for-profit anti-malarial provider aware-
ness of key features of the AMFm programme, and
changes in provider knowledge of appropriate malaria
treatment following AMFm implementation, based on
nationally-representative survey data.
Methods
Study design and sampling
This study had a non-experimental design based on
before-and-after comparisons along with detailed docu-
mentation of implementation process and context, as
recommended in guidelines for the evaluation of com-
plex interventions [19]. Nationally-representative surveys
of outlets stocking anti-malarials were carried out be-
tween August and December 2010 prior to arrival of
AMFm co-paid ACT, and again between October 2011
and January 2012 [20]. Methods for these surveys were
adapted from the ACTwatch project [21].
Outlets were sampled using a stratified cluster sampling
approach, with independent samples drawn at baseline and
endline. Clusters were administrative units with on average
10,000-15,000 inhabitants. Clusters were selected with
probability proportional to population size sampling, with
stratification by urban and rural domains. Within a cluster,
all outlets with the potential to sell anti-malarials were
approached. Eligible outlets included those open at the
time of the visit and with anti-malarials in stock on the day
of the survey or within the previous three months. A full
census of outlets was carried out in Zanzibar due to its
small population size.
Data collection
Data were collected using structured interviews with the
most senior staff member present at the time of the survey.
Questionnaires were harmonized across settings and cre-
ated in English and French, with translation into local lan-
guages where necessary. Questionnaires were administered
by local study staff who had undergone seven days of
standardized training. Quality assurance included daily
supervision as well as random re-interviewing of 5%-15%
of outlets.
Questionnaires covered outlet characteristics as well
as provider awareness and knowledge outcomes (see
Additional file 1 for questionnaire). Respondents’ aware-
ness of the AMFm ‘green leaf ’ logo (located on co-paid
ACT packaging and frequently on promotional mater-
ial), and open-ended questions on the source from
which respondents had seen or heard of the logo, and
their understanding of the meaning of the logo were
included. Additionally, questions were included on
awareness of the subsidy programme, and sources from
which respondents had seen or heard of the subsidy
programme. Respondents were also asked about their
awareness of a RRP for co-paid ACT, and what this RRP
was. In relation to knowledge, respondents’ knowledge
of the first-line recommended anti-malarial for uncom-
plicated malaria and knowledge of the correct dosing
regimen to treat a child under the age of two years
(10 kg) with uncomplicated malaria was tested.
Key informant interviews with national level stake-
holders and document review were used to collect data on
the process of AMFm implementation, including details
of supporting interventions, and of other contextual fac-
tors that could have affected AMFm related outcomes.
Process data were used to devise a number of measures of
intensity of implementation of the communication and
training supporting interventions [22]. These included
months for which co-paid ACT was available, months for
which communication campaigns were implemented, per
capita disbursements for supporting interventions, and
the proportion of private for-profit providers surveyed at
endline who reported that they had attended ‘a training
session about anti-malarials with this [AMFm ‘green leaf ’
logo] symbol’.
Statistical analysis
Data were analysed in Stata v.11. Point estimates were
weighted using survey weights and standard errors calcu-
lated taking into account the clustered and stratified
sampling strategy. Differences in knowledge outcomes be-
tween surveys are expressed in terms of the percentage
point change and 95% confidence intervals. No confidence
intervals are presented for Zanzibar because a complete
census of outlets was done. Additional results by urban
and rural domains, and stratified by sub-category within
the private for-profit sector, are available from the online
additional files.
Ethical approval
Informed oral consent was obtained from all respon-
dents. Ethics approval was obtained from all national
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ethics committees, and from Institutional Review Boards
of ICF International and the London School of Hygiene
and Tropical Medicine.
Results
Table 1 summarizes characteristics of the sample. Re-
sponse rates were high, and over 9,900 and 9,600 private
for-profit outlets were included in baseline and endline
surveys, respectively.
Communication and training activities
The planned package of AMFm communication cam-
paigns and promotional activities was broadly similar
across settings; components generally included are shown
in (Table 2). The AMFm ‘green leaf ’ logo together with
examples of promotional materials are shown in Figure 1.
Promotional messages frequently focused on ACT as rec-
ommended anti-malarial treatment, availability of good
quality ACT identified by the ‘green leaf ’ AMFm logo,
and on the RRP (which was typically not printed on
ACT packaging, but promoted during communication
campaigns).
AMFm-related provider training was conducted for
providers from all sectors in Ghana, Niger, Nigeria,
Uganda and Zanzibar, while private for-profit providers
were targeted in Kenya and Tanzania mainland, and the
public sector in Madagascar. In some settings, private for-
profit importers also carried out training of anti-malarial
providers, running courses for their own distributors and
sponsoring continuous education meetings for professional
bodies (e.g. clinical officers or pharmacists). Private for-
profit importers in some of the pilots also produced their
own promotional materials (Figure 1).
Countries experienced a range of intervention intensities
in the implementation of communication campaigns and
training (Table 3). Ghana and Kenya experienced the
Table 1 Sample description—number of private for-profit outlets screened and number included in baseline (2010)









Outlets interviewed and stocking anti-malarials
at the time of the survey visit†
Ghana
Baseline 55 1 009 960 942 924
Endline 54 752 681 658 646
Kenya
Baseline 57 16 356 12 091 2 110 1 457
Endline 57 12 512 10 539 1 627 1 378
Madagascar
Baseline 38 6 380 6 005 2 064 1 854
Endline 46 9 116 8 559 2 081 1 641
Niger
Baseline 75 3 104 3 098 1 915 1 548
Endline 64 3 102 2 922 1 703 1 337
Nigeria
Baseline‡ 114 5 713 5 171 1 941 1 864
Endline 124 8 345 7 804 1 445 1 393
Tanzania
mainland
Baseline 48 3 042 3 015 612 545
Endline 49 3 708 3 635 734 726
Uganda
Baseline 39 9 692 9 525 1 733 1 590
Endline 44 14 734 14 451 2 453 2 335
Zanzibar‡‡
Baseline - 2 100 2 076 177 171
Endline - 4 134 4 057 227 216
*Outlets that were visited and where at a minimum basic descriptive information was collected. **Outlets that had antimalarial drugs in stock on the day of the
survey or had stocked them in the past three months. † Outlets where antimalarials were in stock on the day of the survey and the interview was completed. ‡
Nigeria baseline data collection done in 2009. ‡‡ A full census was carried out in Zanzibar.
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longest communication campaigns (about nine months),
with Tanzania mainland, Zanzibar and Nigeria experiencing
three to seven months. By contrast, Niger, Madagascar and
Uganda experienced no sustained delivery principally due
to delays or suspension of grants. In Ghana and Zanzibar,
about 40%-50% of anti-malarial providers interviewed re-
ceived training. In Kenya, Niger, Uganda and Tanzania
mainland this was lower at 12% -18%. In total about 2% of
respondents in Madagascar reported receiving some train-
ing, although no official AMFm training interventions for
private sector providers were reported in this setting. Up
until the midpoint of the endline survey, the Global Fund
had disbursed almost 42.3 million dollars (USD) for the im-
plementation of supporting interventions, including com-
munication, training, pharmacovigilance, post-marketing
surveillance, and regulatory interventions (personal com-
munication Melisse Murray, The Global Fund to Fight
AIDS, Tuberculosis and Malaria AMFm secretariat- May
2012). Disbursement per capita ranged from 0.42 USD in
Ghana to 0.06 USD in Niger and Madagascar and 0.03
USD in Tanzania mainland.
In Figure 2 and Table 4, settings are roughly ordered
by intensity of communication campaign and training
implementation, with Ghana and Kenya considered to
have had the greatest intensity, followed by Tanzania
mainland, Zanzibar and Nigeria. Niger, Madagascar and
Uganda were considered to have the lowest intensity of
implementation.
Awareness of the AMFm logo, ACT subsidy programme,
and correct recommended retail price for co-paid ACT
Overall, awareness of the AMFm logo among anti-
malarial providers, measured as whether they remem-
bered having seen the logo before, was 77%-94% in
Ghana, Kenya, Tanzania mainland and Zanzibar; some-
what lower in Uganda (69%) and Nigeria (53%); and low
in Niger and Madagascar (26% and 31%, respectively)
(Figure 2). Recorded awareness in Uganda may have
reflected confusion of the AMFm logo with a pre-
existing leaf logo used on anti-malarials as part of a
separate ACT subsidy project [23]. Awareness among
respondents in urban areas was about 7-percentage
points higher than among respondents in rural areas in
Tanzania mainland and Zanzibar, and between 11–16
percentage points higher than among respondents in
rural areas in Ghana, Kenya, Madagascar, and Niger,
with no substantial differences in Nigeria or Uganda
(Additional file 2). Awareness of the ACT subsidy
programme was lower than awareness of the logo, but
patterns were broadly similar (Figure 2). In general no
Table 3 Implementation ‘intensity’ of AMFm supporting interventions, including communication and training
Country Time from arrival of





preceding the midpoint of
the endline survey*
Percentage of private for-profit outlet
respondents reporting attending a
training session on anti-malarials
‘with this symbol’ (i.e. AMFm logo)
at endline
Disbursement of funding for
supporting interventions
preceding midpoint of endline
survey (USD per capita)**
Ghana 15.5 9 50.2 0.42
Kenya 15 9 12.0 0.18
Tanzania
mainland
13.5 7 18.1 0.03
Zanzibar 6.5 5 37.5 0.11
Nigeria 9.5 3 13.5 0.10
Niger 7 2 12.8 0.06
Madagascar 14 1 2.2 0.06
Uganda 9.5 0 16.6 0.17†
*In some countries there were also some limited communication activities prior to the main roll-out of the communication campaign. For Niger and Madagascar
there were some communication campaign activities but these were suspended prior to endline data collection. In Madagascar the radio and TV campaigns ran
only from April-May 2011 due to a ban on advertising prescription medication directly to the public except during periods of public health emergencies. ** Figures
represent disbursement of Global Fund grants for AMFm supporting interventions including communication campaigns and promotional materials; awareness-
building community-based activities; training of anti-malarial providers; pharmacovigilance and post-marketing surveillance; and regulatory interventions – source:
Global Fund Secretariat. †For Uganda $0.17 per capita disbursement took place, and although expenditure data was not available disbursement of funds took
place less than one month before the midpoint of the endline survey, and no implementation of communication was recorded as taking place in this setting.
Table 2 Components of the AMFm communication
campaigns generally included across all settings
AMFm supporting interventions for communications
• National launch;
• Mass media communication through TV and radio (principally
advertisements, with some TV and radio talk shows);
• Outdoor media (billboards);
• ‘Small media’ (posters);
• Interpersonal media (community meetings and road shows)
Commercial promotion of co-paid ACT
• ‘Small’ media provided by importers and wholesalers of co-paid ACT
(e.g. branded posters and banners displayed within outlets)
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substantial differences were seen between urban and
rural areas in Madagascar, Nigeria or Tanzania mainland.
In Niger, Uganda and Kenya awareness of the ACT sub-
sidy programme was about 6–9 percentage points higher
among respondents from urban outlets, and about 12–
14 percentage points higher among respondents from
urban outlets in Ghana and Zanzibar (Additional file 3).
The most commonly stated source for having seen or
heard of the logo was TV/radio in Ghana, Kenya,
Madagascar and Zanzibar, with 47%-80% of respondents
who had recognised the logo stating this source; and on
malaria medicine packaging in Niger, Nigeria, Tanzania
mainland and Uganda (50%-58%). The most commonly
stated source for having seen or heard of the ACT
subsidy programme was TV/radio in all countries with
56%-94% of respondents stating this source. Other
sources commonly mentioned were: in training; on mal-
aria medicine packaging; in public health facilities; and
on posters/ billboards. Respondents were asked to de-
scribe what the AMFm logo meant to them (multiple
responses were allowed). The most commonly reported
meaning in Ghana, Kenya, Madagascar, Niger and Zanzibar
was “effective/quality anti-malarial”. In Nigeria, Tanzania
mainland and Uganda, the most common meaning was
Figure 2 Awareness of the AMFm ‘green leaf’ logo *the ACT subsidy programme, and the correct recommended retail price for
co-paid ACT at endline (2011) among respondents from private for-profit outlets with anti-malarials in stock on the day of the survey.
*All respondents were shown a visual aid depicting the AMFm logo and were asked whether they have seen the symbol before. Providers are
“able to recognise the AMFm logo” if they answer that they have seen the symbol before. Whiskers show 95% confidence intervals. No
confidence intervals are shown for Zanzibar as a full census was carried out. Results for Madagascar are not presented as no recommended retail
price was set for co-paid ACT in this country. Settings are roughly ordered by intensity of communication campaign and training intervention
implementation (see Table 3).
Table 4 Knowledge of first-line malaria treatment among respondents from private for-profit outlets with anti-malarials
in stock on the day of the survey at baseline (2010) and endline (2011)
Country Baseline (%) Endline (%) Percentage point change (95% confidence interval)
Ghana 73.2 83.3 10.1 (3.1-17.3)
Kenya 44.9 66.1 21.2 (11.5-30.8)
Tanzania mainland 85.6 95.7 10.1 (4.0-16.1)
Zanzibar 77.2 92.1 14.9
Nigeria 14.3 51.2 36.9 (28.7-45.2)
Niger 11.1 27.2 16.1 (11.0-21.2)
Madagascar 12.5 19.4 6.9 (0.9-12.7)
Uganda 74.0 74.8 0.8 (−5.6-7.1)
No confidence interval is shown for Zanzibar as a full census was carried out. Settings are roughly ordered by intensity of communication campaign and training
intervention implementation (see Table 3).
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“ACT.” Other common meanings were “affordable anti-
malarial” and “anti-malarial”.
RRPs for co-paid ACT bearing the AMFm logo were set
in seven of the eight settings, and ranged between 0.46 and
0.96 USD per adult treatment pack. In Madagascar, there
was no RRP, although first-line buyers agreed to maintain a
reasonable mark up of 0.07 USD. Awareness of the correct
RRP for an adult pack was high among respondents in
Ghana and Zanzibar (~80%); and 68% in Kenya and 52% in
Tanzania mainland. Respondents in Niger, Nigeria and
Uganda had very low awareness of the correct RRP (1%-
5%) (Figure 2). Patterns were consistent across urban and
rural areas in Nigeria, Tanzania mainland, and Uganda. In
Kenya and Niger awareness of the correct RRP among
urban respondents was about 9–10 percentage points
higher, while in Zanzibar and Ghana awareness of the
correct RRP among was 13 and 28 percentage points
higher than among rural respondents, respectively
(Additional file 4).
Changes in private for-profit sector provider knowledge
of malaria treatment
At baseline knowledge of the first-line treatment for un-
complicated malaria varied across settings, with high
knowledge in Ghana, Tanzania mainland, Uganda and
Zanzibar, a lower level in Kenya, and low levels in Niger,
Nigeria and Madagascar (Table 4). Improvements of
over 20 percentage points were recorded in Kenya and
Nigeria, and of 7–16 percentage points in Ghana,
Madagascar, Niger, Tanzania mainland and Zanzibar,
with no change in Uganda. Patterns were consistent
across urban and rural areas, with the exception of
Tanzania mainland where the increase in knowledge
was about 10 percentage points higher among rural re-
spondents surveyed (Additional file 5).
Generally increases in knowledge of the correct quality-
assured ACT dosing regimen for a 2 year-old child were
smaller than those seen in respondents’ knowledge of the
recommended first-line treatment for uncomplicated mal-
aria among providers surveyed. At endline knowledge of
the dosing regimen remained low in many settings, despite
increases of between 14–16 percentage points in Ghana
and Uganda, and of 30–33 percentage points in Tanzania
mainland and Zanzibar. Only in Tanzania mainland were
high levels of knowledge recorded at endline (90%)
(Table 5). Patterns were consistent across urban and rural
areas, except in Uganda where increases in knowledge
of the correct quality-assured ACT dosing regimen for
children among urban respondents were 12 percentage
points larger than those recorded among rural respondents,
and Zanzibar where increases in knowledge among rural
respondents were about 10 percentage points higher than
urban respondents (Additional file 6).
Conclusions
Although AMFm implementation was designed to be
broadly similar across settings, the communication and
training components varied considerably across the eight
pilots. Ghana and Kenya had the greatest implementa-
tion intensity, followed by Tanzania mainland, Zanzibar
and Nigeria, with Niger, Madagascar and Uganda having
the lowest intensity.
Our results generally support the interpretation that,
in addition to the availability of co-paid ACT, the inten-
sity of communication campaigns, and particularly the
mass media elements delivered through TV and radio,
contributed to AMFm-related awareness and knowledge
among private for-profit providers. For example, in set-
tings where communication campaigns were imple-
mented for five to nine months, awareness was 76%-94%
for the AMFm logo, 57%-74% for the ACT subsidy
Table 5 Knowledge of paediatric (<2 years of age) quality-assured ACT dosing regimen among respondents from private
for-profit outlets with quality-assured ACT in stock on the day of the survey at baseline (2010) and endline (2011)
Country Baseline (%) Endline (%) Percentage point change (95% confidence interval)
Ghana 31.4 47.8 16.4 (8.7-24.0)
Kenya 67.4 60.6 −6.8 (−17.0-3.5)
Tanzania mainland 60.0 89.5 29.5 (11.7-47.1)
Zanzibar 15.4 48.7 33.3
Nigeria* - 53.7 -
Niger 64.1 43.1 −21.0 (−34.3-7.8)
Madagascar* - 41.6 -
Uganda 64.1 78.5 14.4 (3.3-25.4)
Correct knowledge of paediatric quality-assured ACT dosing regimen was measured as respondents that correctly stated the number of tablets that should be
taken at a time, the number of times the medicine should be taken per day, and the duration of the dose in number of days for child under 2 years (10 kg) for a
specific product which they selected from the quality-assured ACT that they stocked.
Nigeria baseline data collection was conducted in 2009. No confidence interval is shown for Zanzibar as a full census was carried out. Settings are roughly
ordered by intensity of communication campaign and training intervention implementation (see Table 3).
*These data are not available for Madagascar and Nigeria at baseline, as they were not collected in the ACTwatch survey.
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programme, and 52%-80% for the correct RRP. Where
communication campaigns were implemented for three
months or less however, awareness was 26%-69% for the
logo, 12%-36% for the ACT subsidy programme, and <5%
for the RRP.
Communication campaigns also appear to have con-
tributed to improvements in provider knowledge of the
first-line anti-malarial. In six of eight settings, increases
of at least 10 percentage points in private for-profit pro-
viders’ knowledge of the first-line anti-malarial were
seen; with endline knowledge particularly high in Kenya
(66%), Ghana (83%) and Tanzania (mainland and Zanzibar)
(over 90%). In contrast, much smaller improvements were
seen in Madagascar and Uganda. By comparison, in
non-AMFm settings private for-profit provider know-
ledge of the first-line anti-malarial ranged from 42%-
48% across Benin, the Democratic Republic of Congo
and Zambia [24-26].
AMFm-related training also appeared to be linked to
knowledge and awareness outcomes, with the two settings
with the highest training coverage (Ghana and Zanzibar)
performing best at endline on knowledge of the logo and
RRP, and being in the top three settings for knowledge of
the first-line anti-malarial. However, high levels of know-
ledge in some settings with relatively low training coverage
indicate that providers also obtain information through
other sources, such as communications targeted at the gen-
eral public, or through wholesale suppliers.
Given the study design, caution is merited in making
strong causal inferences about the impact of AMFm
supporting interventions. The evaluation was ecological
in design, with exposure estimated at the national level
using proxy measures of duration of implementation.
Moreover, the nationwide nature of AMFm implementa-
tion meant that it was not possible to include comparison
areas. While AMFm-specific awareness is clearly related to
some aspect of the AMFm programme, changes in know-
ledge of the first-line anti-malarial and quality-assured
ACT dosing regimen for children may have been affected
by secular trends or other concurrent malaria communica-
tion campaigns, such as the large scale USAID-funded
Communication and Malaria Initiative in Tanzania (COM-
MIT) programme in mainland Tanzania [27].
Furthermore, these results report awareness among
private for-profit providers only. Awareness among con-
sumers has been reported to be substantially lower in
several settings, though results are only available from
settings with medium to low AMFm implementation in-
tensity. Findings from nationally representative house-
hold surveys in Nigeria, Madagascar and Uganda in
2012 indicate that 13%-40% of caregivers of children
aged less than five years recognised the AMFm logo,
while 9%-18% were aware of the initiative to reduce the
price of ACT. Data from Nigeria and Uganda (where an
RRP was used) show that only 0.1% of those surveyed
were aware of the correct RRP for co-paid ACT [28,29].
There also appears to be a relationship between private
for-profit sector providers’ AMFm-related awareness and
key AMFm outcomes. Countries with the strongest per-
formance in AMFm awareness (Ghana, Kenya, Tanzania
and Zanzibar) generally reported larger increases in avail-
ability and market share of quality-assured ACT in the pri-
vate for-profit sector; larger falls in their price compared to
smaller changes seen in Nigeria and Uganda on the whole;
and minimal changes in Niger and Madagascar [20]. In
contrast, the relationship between improvements in know-
ledge of the first-line anti-malarial and AMFm outcomes
were inconsistent. It is thus possible that AMFm-related
provider awareness may be an important step along a
causal pathway, linking implementation to provider behav-
iour change, though in practice it is challenging to separate
the effect of communications from the reduced price of the
co-paid ACT. Evaluations of mass media campaigns for
other health issues in low and middle-income countries
have shown links to behaviour change of community mem-
bers [6,30,31]. However, other studies have highlighted the
frequent presence of a knowledge-action gap among health
care providers [14].
This study has demonstrated that in settings with strong
implementation of communication campaigns, and in some
cases provider training, there was high AMFm-related
awareness among private for-profit providers within a short
period of AMFm roll out. Substantial improvements in pro-
vider’s knowledge of the first-line drug were also seen.
These results suggest an important role for supporting
interventions, including communication campaigns, in sub-
sidy programmes for public health commodities. However,
to optimize investment in this area more evidence is re-
quired on the relative effectiveness of different supporting
interventions on providers, and on strategies to enhance
consumer awareness.
Additional files
Additional file 1: AMFm questionnaire.
Additional file 2: Provider recognition of AMFm logo at endline
(2011). Provider recognition of AMFm logo (i.e. Providers able to
recognise the AMFm logo (n) as a percentage of the number of outlets
with anti-malarials in stock at the time of the survey visit (N )) at endline
(2011), by anti-malarial outlet type category and urban and rural location.
Note: All respondents were shown a visual aid depicting the AMFm logo
and were asked whether they had seen the symbol before. Providers
were “able to recognise the AMFm logo” if they answered that they had
seen the symbol before. CI = Confidence interval; No confidence intervals
are shown for Zanzibar as a full census was carried out.
Additional file 3: Provider knowledge of the AMFm programme at
endline (2011). Provider knowledge of the AMFm programme (i.e. Providers
who have heard of “a programme that reduces the prices of anti-malarial
medicines known as ACT” (n) as a percentage of outlets with anti-malarials in
stock at the time of the survey visit (N)) at endline (2011), by anti-malarial
outlet type category and urban and rural location. Footnote: CI = Confidence
Willey et al. Malaria Journal 2014, 13:46 Page 8 of 10
http://www.malariajournal.com/content/13/1/46
interval; No confidence intervals are shown for Zanzibar as a full census was
carried out.
Additional file 4: Providers stating the correct recommended retail
price (RRP) for anti-malarials with the AMFm logo at endline (2011).
Providers stating the correct recommended retail price (RRP) for anti-
malarials with the AMFm logo at endline (2011) (i.e. Providers stating the
correct RRP for anti-malarials with the AMFm logo (n) as a percentage of
outlets with anti-malarials in stock at the time of the survey visit (N)) at
endline (2011), by anti-malarial outlet type category and urban and rural
location.Note: No data are shown for Madagascar as an RRP was not set
for co-paid ACTs in this country, CI = Confidence interval; No confidence
intervals are shown for Zanzibar as a full census was carried out.
Additional file 5: Provider knowledge of first-line anti-malarial
treatment at baseline (2010) and endline (2011). Provider knowledge
of first-line anti-malarial treatment at baseline (2010) and endline (2011)
(i.e. Percentage of providers able to correctly identify the anti-malarial for
first-line treatment (n) among outlets with anti-malarials in stock at the
time of the survey visit (N)) baseline (2010) and at endline (2011), by anti-
malarial outlet type category and urban and rural location.Note: Nigeria
baseline data collection was conducted in 2009. CI = Confidence interval;
No confidence intervals are shown for Zanzibar as a full census was
carried out.
Additional file 6: Provider knowledge of dosing regimen for quality-
assured ACT (QAACT) for a child, at baseline (2010) and endline (2011).
Provider knowledge of dosing regimen for quality-assured ACT (QAACT) for a
child, at baseline (2010) and endline (2011) (i.e. Percentage of providers able to
describe correctly the dosing regimen for quality-assured ACT for a child under
2 years of age (<10 kg) (n) among outlets with QAACT in stock at the time of
the survey visit (N)) baseline (2010) and at endline (2011), by anti-malarial
outlet type category and urban and rural location. Note: “describe correctly”
implies that the respondent correctly stated the number of tablets that should
be taken at a time, the number of times the medicine should be taken per
day and the duration of the dose in number of days for child under 2 years
(10kg) for a specific product which they selected from the quality-assured
ACTs that they stocked. These data are not available for Madagascar and
Nigeria at baseline, as they were not collected in the ACTwatch survey. Nigeria
baseline data collection was conducted in 2009. CI = Confidence interval; No
confidence intervals are shown for Zanzibar as a full census was carried out.
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